Royalty Pharma plcRPRXNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+80.2%
5Y CAGR+13.5%
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
+80.2%/yr
Annual compound
5Y CAGR
+13.5%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
1.9x
Solid growth
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025142.31%
2024-5.24%
20239.87%
202224.33%
20210.61%
202075.67%
201967.09%
2018-41.84%
201753.12%
2016-42.75%